Takeda Gastric Cancer Drug Trial: Survival Reaches 10.2 Months
The Takeda gastric cancer drug trial found arcotatug tavatecan lifted median survival to 10.2 months versus 6.9. Results, safety and open questions.
The Takeda gastric cancer drug trial found arcotatug tavatecan lifted median survival to 10.2 months versus 6.9. Results, safety and open questions.